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Natural killer T cells (NKT) recognize lipid antigens in the context of CD1d, a non-polymorphic MHC class I-like molecule. Activation of NKT cells 
has a profound influence on the immune response against tumors and infectious organisms and in autoimmune diseases.
Recent evidence suggests that NKT cell subsets (iNKT/type I and type II) can play opposing roles early in non-microbial liver inflammation.   
A greater understanding of 
NKT subsets’ interplay is 
important, not only for the 
understanding of immune 
regulatory mechanisms in the 
liver, but also to enable the 
development of novel HLA-
independent therapeutics 
for human inflammatory liver 
diseases. 
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is inhibited following sulfatide-mediated activation of type II NKT cells. 
Other type II NKT cells may contribute to HBV-induced hepatitis 
[12]. Thus, differential activation of type II NKT subsets depends 
upon the lipid antigen and state of APCs leading to an exacerbated 
or diminished inflammatory response. Since NKT cells orchestrate 
changes in other cells including DC, NK cells, and adaptive B and T 
cells, they can radically affect the outcome of liver inflammation
Future perspectives
Though animal models may not represent all aspects of human liver 
disease, it is likely that some key immune pathways are conserved 
among species. Since CD1d and NKT-cell systems are extensively 
similar between mice and humans, a greater understanding of NKT 
subsets’ interplay in experimental models is important, not only for the 
understanding of immune regulatory mechanisms in the liver, but also 
to enable the development of novel HLA-independent therapeutics for 
human inflammatory liver diseases. Several key questions still need 
to be addressed: (1) are there similarities in the biological roles of type 
I and type II NKT cells in mice and humans in liver disease? (2) Can 
self-lipid/human CD1d-multimers be utilized for the characterization 
of human NKT cells? (3) Are OPN levels in liver following injury 
modulated by type I NKT cells? (4) Can inhibition of type I NKT cells 
be beneficial in ALD or NAFLD?
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Natural killer T cells (NKT) are innate-like cells which are abundant in liver 
sinusoids and express the cell surface receptors of NK cells (e.g., NK1.1 
(mouse) or CD161+/CD56+(human)) as well as an antigen receptor 
(TCR) characteristic of conventional T cells. NKT cells recognize lipid 
antigens in the context of CD1d, a non-polymorphic MHC class I-like 
molecule. Activation of NKT cells has a profound influence on the immune 
response against tumors and infectious organisms and in autoimmune 
diseases. NKT cells can be categorized into at least two distinct subsets: 
iNKT or type I use a semi-invariant TCR, whereas type II NKT TCRs 
are more diverse. Recent evidence suggests that NKT-cell subsets can 
play opposing roles early in non-microbial liver inflammation in that type 
I NKT are proinflammatory whereas type II NKT cells inhibit type I NKT-
mediated liver injury.
Type I NKT cells are proinflammatory and can promote liver injury
Although type I NKT cells can recognize self-lipids, most also recognize 
a marine sponge-derived lipid α-galactosylceramide (αGalCer) and 
are best identified using αGalCer/CD1d multimers. NKT cells in the 
liver respond very rapidly to injury following either direct recognition of 
cognate lipids or indirectly by TLR ligands and cytokine secretion (e.g., 
IL-12) by activated antigen-presenting cells (APC), such as Kupffer 
cells (KC), hepatocytes, and myeloid dendritic cells (mDC). Notably, 
the cytokine secretion profile (Th1/Th2/Th17-like) of type I NKT is 
influenced by the nature of the APC as well as the lipid ligands, e.g., 
they predominantly secrete IFN-γ following ischemia or toxin-induced 
injury, but secrete both IFN-γ and IL-4 in response to αGalCer [1,2]. 
Rapid secretion of pro-inflammatory cytokines and chemokines by 
type I NKT cells leads to accumulation of CD11b+Gr-1+ cells including 
neutrophils and macrophages in the liver. Accordingly, these cells do 
not accumulate in type I NKT-deficient mice, which are resistant to liver 
injury following ischemic reperfusion injury (IRI), concavalin A (ConA), 
or high-fat diet [1–3]. Type I NKT cells can promote fibrogenesis 
involving the Hedgehog (Hh) pathway and cytokines, including 
osteopontin (OPN), leading to hepatic stellate cell (HSC) activation 
[4]. Activated type I NKT cells can also kill hepatocytes directly (FAS/
FASL) or indirectly by activating NK cells. Collectively, recent studies 
suggest a proinflammatory role of type I NKT cells in liver injury 
following ischemic reperfusion or in sickle cell disease, ConA- or 
thioacetamide (TAA)-induced hepatitis, primary biliary cirrhosis, and 
NAFLD [1,2,4–7]. Though their role remains controversial in obesity 
[8], hepatic type I NKT cells become activated and also secrete IFN-γ 
following a high-fat diet. Since microbial exposure during early life has 
a profound impact on the number and function of NKT cells [9], housing 
and food may influence experimental results in different laboratories.
A major type II NKT subset cross-regulate type I NKT activity and 
protect from liver injury
A major subset of type II NKT cells express oligoclonal TCRs with 
distinct molecular recognition features and can recognize sulfatide, a 
self-glycolipid enriched in the CNS, kidney, and liver [10]. Interestingly, 
anti-sulfatide immune responses are present in multiple sclerosis, 
type 1 diabetes, as well as in hepatitis C virus-associated mixed 
cryoglobulinemia [11], but how sulfatide or other self-lipids are 
presented physiologically has not been investigated yet.
   Type II NKT cells are more abundant in humans than in mice. A 
novel regulatory mechanism in the liver is orchestrated following 
activation of type II NKT cells by sulfatide, which limits tissue damage 
[1,2]. Sulfatide administration results in activation of plasmacytoid 
DC (pDC), but tolerization of mDC followed by anergy induction in 
type I NKT cells [2]. Both anergic type I NKT cells and tolerized mDC 
also inhibit expansion of adaptive immunity. Tolerized mDC may also 
control inflammation through IL-10 secretion and they are abundant in 
the human liver as well. Thus, a cascade of proinflammatory events Journal of Hepatology 2013 vol.  59 | 618–620 619
Fig. A proinflammatory and protective role of type I and a major type II NKT subset, respectively, in non-microbial liver inflammatory disease. APC, antigen-presenting cells; mDC 
and pDC, myeloid and plasmacytoid dendritic cells; Hh, Hedgehog pathway; OPN, osteopontin; HSC, hepatic stellate cells.
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